Back to products

Degalix 120 mg Injection

Brand Name: Degalix

Molecule: Degarelix

Strength: 120 mg

Quantity: 1 Vial

Form: Injection

Packaging Type: Vial

Manufacturer/Marketed By: BDR Pharma

Country of Origin: India

No similar products found.

Overview

- Introduction
- Benefits
- Indications and Usage
- How it Works
- Dosage & Administration
- Side Effects
- Warning and Precaution
- Patient Guidance
- Clinical Trial & Approvals
- References
- FAQ

Description

Degalix 120mg Degarelix Injection are manufactured by BDR Pharmaceuticals in India and contain 120mg of Degarelix 120mg per injection. Each Vial includes Pack of 1 Vial, making Degalix 120mg Degarelix Injection an effective option for Prostate Cancer . Prescription Required from your healthcare provider to purchase Degarelix 120mg medicine. Indogenmed deals in all type of generic Degarelix 120mg medicine.

Benefits

Rapidly reduces testosterone levels, which may help slow prostate cancer growth
Does not cause an initial testosterone surge (flare) seen with some other hormone therapies
Used as part of androgen deprivation therapy for prostate cancer
Administered under medical supervision in a clinical setting
Helps support long-term management of advanced prostate cancer

Indications and Usage

Degalix (degarelix) may be prescribed for:

Advanced prostate cancer
Hormone therapy aimed at reducing testosterone levels
Patients requiring androgen deprivation therapy (ADT) for prostate cancer management

Treatment decisions are based on disease stage, PSA levels, and clinical evaluation.

How it Works

Degarelix works by blocking gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland. Normally, GnRH stimulates the release of hormones that lead to testosterone production in the testes. Testosterone can promote the growth of prostate cancer cells.

By directly inhibiting GnRH receptors, degarelix quickly reduces the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This leads to a rapid decrease in testosterone levels, which may help slow the growth and spread of prostate cancer when the medicine is used as prescribed and monitored by a healthcare professional.

Dosage & Administration

Degalix is administered as a subcutaneous injection, usually in the abdominal region.
The injection should be given by trained healthcare professionals.
Treatment typically begins with an initial loading dose, followed by maintenance injections at regular intervals.
Dosage and treatment schedules are determined by the treating physician based on clinical needs.
Patients may require regular monitoring of testosterone and PSA levels during therapy.

Side Effects

Common side effects

Injection site reactions (pain, redness, swelling)
Hot flashes
Weight gain
Fatigue
Increased liver enzymes
Sweating

Serious side effects

Severe allergic reactions
Heart rhythm problems (QT prolongation)
Liver function abnormalities
Bone thinning with long-term use
Metabolic changes such as increased blood sugar

Patients should seek medical attention if severe symptoms occur.

Warning and Precaution

Possible heart rhythm changes (QT prolongation)
Monitor liver function and hormone levels during treatment
Injection site reactions are common
Long-term therapy may contribute to bone density loss
May cause metabolic changes such as increased blood sugar
Inform healthcare providers about all medications and supplements before starting treatment

Patient Guidance

Injections should be administered by healthcare professionals
Attend all scheduled follow-up appointments and monitoring tests
Report symptoms such as severe injection reactions, chest pain, or irregular heartbeat
Maintain regular monitoring of PSA levels and testosterone levels
Inform your doctor about other medications or medical conditions
Follow your healthcare provider’s advice regarding diet, exercise, and bone health

Clinical Trial & Approvals

Degarelix has been evaluated in clinical trials studying hormone therapy for advanced prostate cancer. Studies demonstrated that degarelix effectively reduces testosterone levels without causing an initial hormone surge. Based on these findings, degarelix has received approvals from regulatory agencies including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of advanced prostate cancer.

References

U.S. Food and Drug Administration (FDA) – Degarelix Prescribing Information
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022201s016lbl.pdf
European Medicines Agency (EMA) – Degarelix Product Information
https://www.ema.europa.eu/en/medicines/human/EPAR/firmagon
National Cancer Institute – Degarelix Drug Information
https://www.cancer.gov
Drugs.com – Degarelix Drug Information
https://www.drugs.com
ClinicalTrials.gov – Degarelix Clinical Studies
https://clinicaltrials.gov

Prescription & documentation note

Degalix 120 mg Injection is typically supplied against a valid prescription and administered by healthcare professionals. For international supply requests, patients may need to provide documentation such as a licensed physician’s prescription, medical records, and identification, depending on destination country regulations. MedsMonk can assist with documentation guidance where applicable.